德华制药公司对TEV-749长效精神分裂症注射的SOLARIS第三期试验显示显著改善,没有注射后妄想/镇静综合征. Teva Pharmaceuticals' Phase 3 SOLARIS trial for TEV-749 long-acting schizophrenia injection shows significant improvements and no post-injection delirium/sedation syndrome.
Teva制药公司宣布,其第三阶段对TEV-749进行SOLARIS试验取得了积极成果,TEV-749是精神分裂症的长效注射。 Teva Pharmaceuticals announced positive results from its Phase 3 SOLARIS trial for TEV-749, a long-acting injection for schizophrenia. 该研究达到了其主要终点,表明与安慰剂相比,阳性和负性综合症比例表(PANSS)和关键的次要措施有了显著改善。 The study met its primary endpoint, showing significant improvements in the Positive and Negative Syndrome Scale (PANSS) and key secondary measures compared to placebo. 重要的是,没有出现注射后妄想/镇静综合征的病例,这是现有治疗的主要问题. Importantly, there were no cases of post-injection delirium/sedation syndrome, addressing a major concern with existing treatments. 这可以为需要长效疗法的病人提供新的选择。 This could provide a new option for patients needing long-acting therapy.